Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2019-11-17 Regulatory Filings
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Response to ASX Appendix 3Y Query 3 pages 301.8KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX (Australian Securities Exchange) to Vectus Biosystems Limited regarding a late lodgement of an Appendix 3Y, which is a Change of Director's Interest Notice. The letter requests explanations and information about compliance with listing rules related to director disclosures. The content focuses on regulatory compliance and disclosure obligations rather than financial results, management changes, or other report types. It is a regulatory inquiry and response about director shareholding disclosures, not a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-11-17 English
Appendix 4C - quarterly 6 pages 406.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting. It contains detailed financial data including cash flow statements, financing activities, and estimated cash outflows for the next quarter. The document covers the quarter ended 30 September 2019 and includes operational commentary, research updates, patent information, and financing details. The length of the document (over 14,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-10-30 English
Change of Director's Interest Notice - PB 3 pages 252.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the conversion of performance rights into shares. This type of document is a formal notification of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document is about a director's interest change, not a general regulatory filing or announcement of a report. Therefore, the correct classification is 'DIRS'.
2019-10-27 English
Notice of Annual General Meeting/Proxy Form 14 pages 900.2KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF 2019 ANNUAL GENERAL MEETING' for Vectus Biosystems Limited and includes detailed agenda items typical of an AGM notice, such as election of directors, adoption of remuneration report, and approval of convertible notes issuance. It references the Annual Report for the year ended 30 June 2019 but does not contain the report itself. The document is a notice and explanatory notes for the AGM, instructing shareholders on voting and proxy procedures. It does not contain financial statements or substantive financial data but rather serves as the meeting notice and agenda. Therefore, it fits the category of AGM Information (AGM-R).
2019-10-20 English
Publication of preclinical data in model of cardiac fibrosis 2 pages 226.6KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about the publication of preclinical research data related to a therapeutic development by Vectus Biosystems Limited. It discusses scientific findings, the significance of the research, and the company's development pipeline and strategy. There is no indication of financial statements, regulatory filings, shareholder meeting materials, or any formal report type such as Annual Report, Interim Report, or Earnings Release. The document is primarily a press release announcing a scientific publication and company progress, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2019-10-07 English
Appendix 3B - issue of shares & options 11 pages 812.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 3 October 2019 from Vectus Biosystems Limited to the Australian Securities Exchange (ASX). It details the issuance of new shares and options, including specifics about the number of securities issued, terms of the options, and compliance with relevant sections of the Corporations Act 2001. The document includes an Appendix 3B, which is a standard form used in Australian securities markets for new issue announcements and applications for quotation of additional securities. The content focuses on the issuance of shares and options, their terms, and regulatory compliance, without containing financial statements or performance data. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains detailed information about the securities issued, so it is not merely an announcement of a report or a short notice. Therefore, the appropriate classification is CAP with high confidence.
2019-10-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.